ChiCTR2100047343 版本V1.3 版本创建时间2022/02/06 23:00:34 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100047343 

最近更新日期:

Date of Last Refreshed on:

2022-02-06 22:59:22 

注册时间:

Date of Registration:

2021-06-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

脑微出血及其分度的相关危险因素分析

Public title:

Analysis of risk factors related to cerebral microhemorrhage and its grading

注册题目简写:

English Acronym:

研究课题的正式科学名称:

脑微出血及其分度的相关危险因素分析

Scientific title:

Analysis of risk factors related to cerebral microhemorrhage and its grading

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

戴悦 

研究负责人:

李云涛 

Applicant:

Dai Yue 

Study leader:

Li Yuntao 

申请注册联系人电话:

Applicant telephone:

+86 15282059295

研究负责人电话:

Study leader's telephone:

+86 13770750763

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1018717902@qq.com

研究负责人电子邮件:

Study leader's E-mail:

liyuntao78@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市鼓楼区汉中路140号

研究负责人通讯地址:

江苏省南京市鼓楼区世茂外滩

Applicant address:

140 Hanzhong Road, Gulou District, Nanjing, Jiangsu

Study leader's address:

Shimao Bund, Gulou District, Nanjing, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京医科大学

Applicant's institution:

Nanjing Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2021)-KY-075-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京医科大学第二附属医院医学伦理委员会

Name of the ethic committee:

the medical ethics committee of Nanjing Medical University Second Affiliated Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-03-24 00:00:00

伦理委员会联系人:

张娟

Contact Name of the ethic committee:

Zhang Juan

伦理委员会联系地址:

江苏省南京市鼓楼区姜家园路121号

Contact Address of the ethic committee:

121 Jiangjiayuan Road, Gulou District, Nanjing, Jiangsu

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京医科大学第二附属医院

Primary sponsor:

Nanjing Medical University Second Affiliated Hospital

研究实施负责(组长)单位地址:

江苏省南京市鼓楼区姜家园路121号

Primary sponsor's address:

121 Jiangjiayuan Road, Gulou District, Nanjing, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京医科大学第二附属医院

具体地址:

鼓楼区姜家园路121号

Institution
hospital:

Nanjing Medical University Second Affiliated Hospital

Address:

121 Jiangjiayuan Road, Gulou District

经费或物资来源:

南京医科大学第二附属医院

Source(s) of funding:

Nanjing Medical University Second Affiliated Hospital

Target disease:

cerebral microhemorrhage

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

探讨脑微出血可能存在的各项危险因素,为预防脑微出血及治疗提供依据,进而改善患者长期预后及生活质量。  

Objectives of Study:

To explore the possible risks factors of cerebral microhemorrhage, so as to provide evidence for the prevention and treat ment of cerebral microhemorrhage,and to improve the long-term prognosis and quality of life of patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.能配合行脑ESWAN检查;
2.通过病历资料等能收集到完整的调查资料。

Inclusion criteria

1. Can cooperate with brain ESWAN examination;
2. Complete investigation data can be collected through medical records, etc.

排除标准:

1.凝血系统障碍性疾病;
2.脑肿瘤、脑外伤、脑血管畸形、颅内感染等可引起的脑出血的疾病;
3.严重内科疾病(心、肺、肾等功能衰竭)患者。

Exclusion criteria:

1. Disorders of the coagulation system;
2. Brain tumor, brain injury, cerebrovascular malformation, intracranial infection and other diseases that can cause cerebral hemorrhage;
3. Severe medical diseases (heart, lung, kidney and other functional failure patients.

研究实施时间:

Study execute time:

From 2021-06-12 00:00:00 To 2022-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-06-12 00:00:00 To 2022-06-30 00:00:00  

干预措施:

Interventions:

组别:

连续入组

样本量:

160

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China 

Province:

Jiangsu 

City:

Nanjing 

单位(医院):

南京医科大学第二附属医院 

单位级别:

三甲 

Institution
hospital:

Nanjing Medical University Second Affiliated Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血压

指标类型:

主要指标

Outcome:

blood pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖

指标类型:

主要指标

Outcome:

blood glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂

指标类型:

主要指标

Outcome:

blood fat

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

主要指标

Outcome:

liver function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

凝血功能

指标类型:

主要指标

Outcome:

coagulation function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

年龄

指标类型:

主要指标

Outcome:

age

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑白质病

指标类型:

主要指标

Outcome:

leukodystrophy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

吸烟

指标类型:

主要指标

Outcome:

smoke

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

饮酒

指标类型:

主要指标

Outcome:

drink

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 25 years
最大 Max age 92 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

未使用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not used

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022-06-30 请说明共享原始数据的方式

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2022-06-30

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-06-12 22:29:47